Pipeline

Proof of concept to be generated by 5 clinical trials

Indications	Protocol	Location	Development Stage
			Preclinical	Phase 1	Phase 2	Phase 3
Brain Metastases	NANORAD 2 CHU Grenoble-Alpes 100 patients randomized		Recruiting Phase 2
Brain Metastases	NANOBRAINMETS Dr. Aizer at Dana-Farber/Harvard Cancer Center 134 patients randomized		Recruiting Phase 2
Glioblastoma	NANO-GBM Centre Jean Perrin 66 patients randomized		Recruiting Phase 1
Pancreatic/ Non Small Cell Lung Cancer	NANOSMART Dr. Leeman at Dana-Farber/Harvard Cancer Center 100 patients randomized		Recruiting Phase 1
Cervical Cancer	NANOCOL Institut Gustave Roussy 12 patients		Recruitment completed

ODD: Orphan Drug Designation obtained from both the FDA and the EMA

: Phase 2 protocol approved